source
- Experimental drugs to lower Lp(a) move toward market, promising billions in potential salesHigh levels of lipoprotein(a), or Lp(a), are a genetic risk factor for heart disease that affects roughly one in five people and currently has no approved therapy. Several drugmakers are moving ex…
- Aurora Therapeutics halts lead CRISPR program and cuts staffAurora Therapeutics, founded as the first company dedicated to developing custom CRISPR-based gene-editing medicines, announced a major restructuring. The firm said it is laying off several employ…